These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20025819)

  • 1. Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitology; 2010 Apr; 137(5):871-80. PubMed ID: 20025819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitology; 2011 Feb; 138(2):224-36. PubMed ID: 20946692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitology; 2009 Feb; 136(2):183-92. PubMed ID: 19079818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):981-95. PubMed ID: 21442257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2010 Jul; 107(2):337-53. PubMed ID: 20512589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the P-glycoprotein inhibitor, R(+)-verapamil on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Vet Parasitol; 2013 Jul; 195(1-2):72-86. PubMed ID: 23597772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased susceptibility of a triclabendazole (TCBZ)-resistant isolate of Fasciola hepatica to TCBZ following co-incubation in vitro with the P-glycoprotein inhibitor, R(+)-verapamil.
    Meaney M; Savage J; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2013 Sep; 140(10):1287-303. PubMed ID: 23756576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
    Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
    Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Vet Parasitol; 2011 May; 177(3-4):305-15. PubMed ID: 21208747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Vet Parasitol; 2012 Feb; 184(1):37-47. PubMed ID: 21872399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2010 May; 106(6):1351-63. PubMed ID: 20336319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):1209-23. PubMed ID: 21858480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Exp Parasitol; 2013 Nov; 135(3):642-53. PubMed ID: 24090567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica.
    Toner E; Brennan GP; McConvery F; Meaney M; Fairweather I
    Parasitology; 2010 Apr; 137(5):855-70. PubMed ID: 20030907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep.
    Virkel G; Lifschitz A; Sallovitz J; Ballent M; Scarcella S; Lanusse C
    J Vet Pharmacol Ther; 2009 Feb; 32(1):79-86. PubMed ID: 19161459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.
    McConville M; Brennan GP; Flanagan A; Edgar HW; Hanna RE; McCoy M; Gordon AW; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2009 May; 162(1-2):75-88. PubMed ID: 19282108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep.
    Virkel G; Lifschitz A; Sallovitz J; Pis A; Lanusse C
    J Vet Pharmacol Ther; 2006 Jun; 29(3):213-23. PubMed ID: 16669866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
    McConville M; Brennan GP; McCoy M; Castillo R; Hernandez-Campos A; Ibarra F; Fairweather I
    Parasitology; 2006 Aug; 133(Pt 2):195-208. PubMed ID: 16650337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.